Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor Patients

Inclusion criteria: * Patients with solid tumor for which no standard therapy is available. * At the recommended dose (expansion cohort): only patients with measurable disease and MET gene amplification. Exclusion criteria: * Patient less than 20 years old. * ECOG performance status \>2. * Poor bone marrow reserve as defined by absolute neutrophils count \<1.5 x 10\^9/L or platelets \<100 x 10\^9/L. * Poor organ function as defined by one of the following: * Total bilirubin \>1.5 x ULN. * AST, ALT, alkaline phosphatase \>2.5 x ULN or \>5 x ULN in case of documented liver metastasis. * Serum creatinine \>1.5 x ULN, or serum creatinine between 1.0 and 1.5 x ULN associated with calculated creatinine clearance \<60 mL/min. * Proteinuria \>500mg/24h. * Pregnant or breast-feeding women. * Sexually active (males and females) who do not agree to use medically acceptable methods of contraception during the course of the study and for 3 months following discontinuation of study drug. * Female patients of childbearing potential must have a negative pregnancy test at screening. * Known or symptomatic brain metastasis (other than totally resected or previously pre-irradiated and no progressive/relapsing) or lepto-meningeal carcinomatosis. * No resolution of any specific toxicities (excluding alopecia) related to any prior anti-cancer therapy to grade ≤1 according to the NCI CTCAE v.4.03. * Wash out period of less than 3 weeks from previous antitumor therapy or any investigational treatment,(and less than 6 weeks in case of prior nitrozo-urea and or mitomycin C treatment). * Any surgery with major risk of bleeding performed less than 10 days prior to study treatment administration. * Any other severe underlying medical conditions, which could impair the ability to participate in the study. * Patients treated with potent CYP3A inhibitor. * Patients treated with potent and moderate CYP3A inducers. * Known hypersensitivity or any adverse event related to the study drug excipient (Captisol®). * Prior treatment with any MET inhibitor compound (selective or not). The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.